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Abstract: Diabetes mellitus is known to exacerbate cerebral ischemic injury. In the 
present study, we investigated antiapoptotic and anti-inflammatory effects of oral 
supplementation of ascorbic acid (AA) on cerebral injury caused by middle cerebral 
artery occlusion and reperfusion (MCAO/Re) in rats with streptozotocin-induced 
diabetes. We also evaluated the effects of AA on expression of sodium-dependent 
vitamin C transporter 2 (SVCT2) and glucose transporter 1 (GLUT1) after MCAO/Re 
in the brain. The diabetic state markedly aggravated MCAO/Re-induced cerebral damage, 
as assessed by infarct volume and edema. Pretreatment with AA (100 mg/kg, p.o.) for 
two weeks significantly suppressed the exacerbation of damage in the brain of diabetic 
rats. AA also suppressed the production of superoxide radical, activation of caspase-3, 
and expression of proinflammatory cytokines (tumor necrosis factor-α and 
interleukin-1β) in the ischemic penumbra. Immunohistochemical staining revealed that 
expression of SVCT2 was upregulated primarily in neurons and capillary endothelial 
cells after MCAO/Re in the nondiabetic cortex, accompanied by an increase in total AA 
(AA + dehydroascorbic acid) in the tissue, and that these responses were suppressed in 
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the diabetic rats. AA supplementation to the diabetic rats restored these responses to the 
levels of the nondiabetic rats. Furthermore, AA markedly upregulated the basal 
expression of GLUT1 in endothelial cells of nondiabetic and diabetic cortex, which did 
not affect total AA levels in the cortex. These results suggest that daily intake of AA 
attenuates the exacerbation of cerebral ischemic injury in a diabetic state, which may be 
attributed to anti-apoptotic and anti-inflammatory effects via the improvement of 
augmented oxidative stress in the brain. AA supplementation may protect endothelial 
function against the exacerbated ischemic oxidative injury in the diabetic state and 
improve AA transport through SVCT2 in the cortex. 
Keywords: ascorbic acid; diabetes mellitus; oxidative stress; apoptosis; proinflammatory; 
cytokine; sodium-dependent vitamin C transporter 2 (SVCT2); glucose transporter 1 
(GLUT1); rat; streptozotocin; middle cerebral artery occlusion and reperfusion 
 
1. Introduction 
Diabetes mellitus is a metabolic disorder associated with chronic hyperglycemia, which is 
known to enhance systemic oxidative stress, predisposing to diabetic complications. Diabetes is a 
major risk factor for atherosclerotic diseases such as acute brain ischemia [1,2]. Moreover, it 
increases the risks of morbidity and mortality after stroke [3,4]. Oxidative stress plays an essential 
role in the pathogenesis of transient cerebral ischemic injury [3–5]. In particular, reperfusion after a 
long period of vessel occlusion triggers the explosive generation of reactive oxygen species (ROS), 
such as superoxide radical (O2–), hydroxyl radical, hydrogen peroxide, etc., which causes apoptosis 
and delayed death of cells through oxidative damage to lipids, proteins, and DNA in the ischemic 
penumbral region [6–9]. In addition to apoptotic cell death, inflammatory neurodegeneration is 
another crucial process contributing to cerebral damage after ischemia and reperfusion [10]. ROS 
have been shown to activate nuclear factor-κB, which enhances the transcription of the genes 
encoding proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β 
(IL-1β), leading to inflammatory responses [11]. Myeloperoxidase (MPO) expressed by microglia, a 
histopathological marker of inflammation, generates cytotoxic ROS and leads to further 
inflammatory damage in the ischemic tissue [12]. Accumulating evidence indicates that 
hyperglycemia in diabetes is associated with a decrease in the antioxidant potential and an increase 
in ROS generation [13–15]. In addition, diabetes has been shown to be a proinflammatory state that 
increases the risk of vascular complications [16,17]. Thus, the enhanced oxidative stress and 
inflammatory responses in the diabetic state may substantially contribute to the aggravation of 
cerebral injury caused by transient ischemia and subsequent reperfusion. 
L-ascorbic acid (AA) is an essential antioxidant for scavenging free radicals in the brain.  
AA participates not only in sustaining the normal function of the central nervous system (CNS) but 
in ameliorating the damage induced by pathological conditions that increase the generation of  
ROS [18]. The CNS maintains relatively high concentrations of AA, indicating a neuroprotective 
role for AA [19]. The transport of AA from the plasma to the CNS is mainly mediated by 
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sodium-dependent vitamin C transporter 2 (SVCT2). In addition, glucose transporter 1 (GLUT1) is 
located in the endothelial cells of the blood–brain barrier (BBB) and transports oxidized AA 
([dehydroascorbic acid (DHA)) as another source of AA to the brain. Upregulation of SVCT2 [20] 
and GLUT1 [21] expression has been demonstrated in rats with cerebral ischemic injury, which 
suggests that AA is necessary for protection against oxidative neuronal injury. The concentration of 
AA is considered to reflect oxidative stress in animal tissues sensitively [22]. Patients with 
ischemic stroke or diabetes have lower concentrations of AA in the plasma, suggesting that a 
systemic decrease in AA is a consequence of enhanced consumption of AA by elevated oxidative 
stress [23,24]. In a previous study, we demonstrated that chronic supplementation with AA 
attenuates oxidative stress in both the plasma and the brain and alleviates cerebral injury induced 
by middle cerebral artery occlusion and reperfusion (MCAO/Re) in rats with streptozotocin 
(STZ)-induced diabetes [25]. We showed that the activity of antioxidant enzymes (superoxide 
dismutase, catalase, and glutathione peroxidase) is decreased, and lipid peroxidation is accelerated 
in the brain of diabetic rats; those detrimental oxidative processes are inhibited by AA 
supplementation. These data suggest that the enhanced oxidative stress in the diabetic state causes 
the functional impairment of antioxidant enzymes, and the resulting diminution in antioxidative 
defense can cause further enhancement of the generation of ROS and subsequent neuronal 
apoptosis and inflammatory neurodegeneration in the ischemic brain. Nonetheless, there is a 
shortage of studies so far on the antiapoptotic and anti-inflammatory effects of AA in cerebral 
ischemia with diabetes. 
In the present study, we evaluated the effects of chronic oral pretreatment with AA on the 
production of O2– and on apoptosis in the brain after MCAO/Re in rats with STZ-induced diabetes. 
To test whether AA suppresses inflammatory responses induced by MCAO/Re, we also examined 
the effects of AA on the expression of TNF-α, IL-1β, and MPO in the brain. Although the transport 
of AA to the CNS is an important factor for its neuroprotection, changes in expression of SVCT2 
and GLUT1 proteins in response to AA supplementation and/or cerebral ischemia in diabetic state 
have not been reported. Therefore, we investigated the effects of AA supplementation on the 
expression of SVCT2 and GLUT1 after MCAO/Re in the brain of diabetic rats. 
2. Experimental Section 
2.1. Experimental Animals 
Animal care and surgical procedures were performed in accordance with guidelines approved by 
the National Institutes of Health (Bethesda, MD, USA) and the Josai University Animal Research 
Committee. Male Sprague-Dawley rats (4 weeks old, weight 120–140 g) were purchased from Japan 
SLC (Shizuoka, Japan) and were housed under standard conditions with a temperature-controlled 
environment (23 °C ± 0.5 °C) and a 12 h light/dark cycle. The animals were allowed free access to 
rodent chow (CE-2, CLEA Japan, Tokyo, Japan) and water. Type 1 diabetes was induced in the rats 
(diabetic group) by a single intraperitoneal injection of STZ (50 mg/kg of body weight) dissolved in 
0.1 mM sodium citrate, pH 4.5, while the normal control rats (nondiabetic group) were injected with 
the buffer only [26]. Seven days after the injection of STZ, a blood sample was collected by tail vein 
paracentesis, following which plasma glucose was measured using a glucose analyzer (Ascensia, 
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Bayer Yakuhin, Osaka, Japan). Diabetes was defined as a blood glucose level greater than 300 mg/dL. 
Then, the diabetic and nondiabetic groups were divided into 2 groups and were housed for an 
additional 6 weeks until stroke was induced by MCAO/Re. AA (L-Ascorbic acid, Wako Pure 
Chemicals Industries, Osaka, Japan) (100 mg/kg; nondiabetic and diabetic AA-supplemented 
groups) or distilled water (nondiabetic and diabetic control groups) was orally administered 
through nasogastric tube once daily for the last 2 weeks. AA was stored at +4 °C, and dissolved in 
distilled water fresh each time just before administration. 
2.2. MCAO/Re 
The experimental MCAO/Re rat model was prepared as described previously [25]. The rats 
were anesthetized with halothane (4% for induction and 1.5% for maintenance) under spontaneous 
respiration. After a midline incision on the neck, the right common carotid artery was isolated 
under an operating microscope. All branches of the external carotid artery were ligated. The tip of a 
4–0 surgical nylon monofilament rounded by flame heating was inserted through the internal 
carotid artery and advanced to occlude the origin of MCA. The rectal temperature was maintained 
at 37 °C with a heat lamp and a heating pad during the operation. After 2 h of occlusion, the 
filament was withdrawn to enable reperfusion. The distance from bifurcation of the common 
carotid artery to the tip of the suture was approximately 20 mm in all rats. Cerebral blood flow was 
detected using a Laser Doppler flowmetry (ATBF-LC1, Unique Medical, Tokyo, Japan), and 
approximately 50% reduction of its baseline associated with MCAO was ascertained in the rats. 
Then, the rats were allowed to recover from anesthesia at room temperature and were killed after 
24 h of reperfusion. Sham operation involved the same manipulations but insertion of the filament. 
2.3. Infarct and Edema Assessment 
After 24 h of reperfusion, the rats were subjected to general halothane anesthesia and 
decapitated. The brain was immediately removed and placed in ice-cold saline. Each brain was 
then cut into 2 mm coronal slices in a rat brain matrix. The brain slices were immediately 
immersed in 2% 2,3,5-triphenyl tetrazolium chloride (TTC, Wako Pure Chemicals Industries, 
Osaka, Japan) at 37 °C for 15 min and then in 4% formaldehyde [26,27]. Infarct areas were 
identified using an image analysis system (Scion Image 1.62, Frederick, MD, USA) and were 
combined to obtain the infarct volumes per brain according to the following formula: corrected 
infarct volume (%) = (left hemisphere volume − (right hemisphere volume − the infarct volume)) × 
100/left hemisphere volume. Edema in the ischemic hemisphere was also calculated as follows: 
edema (%) = (right hemisphere volume − the infarct volume)/left hemisphere volume × 100. 
2.4. Neurological Evaluation 
Postischemic neurological deficits were evaluated after 24 h of reperfusion on a 5-point scale as 
follows: grade 0, no deficit; grade 1, failure to fully extend the right forepaw; grade 2, spontaneous 
circling or walking to a contralateral side; grade 3, walking only when stimulated; grade 4, 
unresponsive to stimulation and a depressed level of consciousness; and grade 5, death [25,27]. 
Before MCAO, the neurological score was zero in all the rats. The rats that did not exhibit 
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neurological deficits after MCAO/Re were excluded from the study. Grades of the neurological 
score were evaluated by an investigator blinded to the treatment protocol. 
2.5. Detection of O2− Production in the Brain 
Detection of intracellular O2− production in the ischemic penumbral region of the cortex after 
MCAO/Re was performed by histochemical staining of freshly frozen brain sections (8 μm thick) 
with the fluorescent probe dihydroethidium (DHE). The brain sections were immediately incubated 
with DHE (10 μmol/L, Sigma-Aldrich Japan, Tokyo, Japan) in phosphate-buffered saline for  
30 min at 37 °C [28,29]. To determine the fluorescence intensity of oxidized DHE, 3 visual fields 
within the penumbral cortex regions of each hemisphere were photographed using a confocal laser 
scanning microscope (Fluoview FV1000, OLYMPUS, Tokyo, Japan) with excitation at 510 nm and 
emission at 580 nm. Fluorescence intensity of oxidized DHE was quantified using imaging software  
(FV10-ASW 1.7, OLYMPUS, Tokyo, Japan). Analyses of immunohistochemistry were performed 
by an investigator blinded to the treatment protocol. 
2.6. Immunohistochemistry 
Immunohistochemical staining was performed as described previously [20,30,31]. The brain was 
fixed with 4% phosphate-buffered paraformaldehyde. Coronal brain sections (8 μm thick) were 
incubated with 3% hydrogen peroxide for 40 min at room temperature to inhibit endogenous 
peroxidase and then incubated with blocking buffer (4% Block Ace, Dainippon Sumitomo Pharma, 
Osaka, Japan) for 2 h. Then, the slices were incubated with polyclonal rabbit anti-IL-1β antibody 
(1:300, Santa Cruz Biotechnology, Dallas, TX, USA), polyclonal rabbit anti-TNF-α antibody 
(1:200, Rabbit mAb, Hycult Biotech, Uden, The Netherlands), polyclonal rabbit anti-cleaved 
caspase-3 antibody (1:100, Cell Signaling Technology, Danvers, MA, USA), or monoclonal mouse 
anti-MPO (1:100, Hycult Biotech, Uden, The Netherlands), polyclonal rabbit anti-SVCT2 antibody 
(1:100, Santa Cruz Biotechnology, Dallas, TX, USA), polyclonal rabbit anti-GLUT1 antibody 
(1:100, Santa Cruz Biotechnology, Dallas, TX, USA) in 0.01 mol/L phosphate-buffered saline 
overnight at 4 °C. In a double-immunohistchemical study for determination of the cell types of 
expressing SVCT2 or GLUT1, monoclonal mouse anti-neuronal nuclei (NeuN) antibody (1:300, 
Millipore, Billerica, MA, USA) and monoclonal mouse anti-rat endothelial cell antigen (RECA1) 
antibody (1:200, Abcom, Cambridge, UK) were used. After washing with phosphate-buffered 
saline, the slices were incubated with either Cy3- or FITC-conjugated secondary antibody (1:200, 
Millipore, Billerica, MA, USA) for 2 h at room temperature. Finally, the sections were incubated 
with the nuclear stain TO-PRO-3 (1:10,000, Invitrogen, Carlsbad, CA, USA) in phosphate-buffered 
saline for 10 min at room temperature with gentle agitation. Immunofluorescence was visualized 
using the laser scanning confocal microscope and the intensity was measured using the imaging 
software. Three sections per rat and 3–4 rats per group were used for the analyses. 
2.7. Real-Time Polymerase Chain Reaction (PCR) Analysis 
The expression levels of SVCT2 (Slc23a2) and GLUT1 (Slc2a1) mRNA were assessed by 
quantitative real-time polymerase chain reaction (PCR) as described previously [32]. The rats 
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subjected to MCAO were killed after 24 h of reperfusion, and total RNA samples were prepared 
from the ischemic penumbral cortex of each rat. Total RNA was extracted using the RNeasy Mini 
Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. Total RNA (500 pg) 
from each sample was reverse-transcribed with oligo-dT and random hexamer primers using 
reverse transcriptase (PrimeScript RT Enzyme Mix I; Takara RNA PCR Kit, Takara Biomedicals, 
Shiga, Japan). Real-time PCR was performed with 10 ng of cDNA and a pair of gene-specific 
primers (Takara Biomedicals, Shiga, Japan) that were added to the SYBR Premix EX Taq (Takara 
Biomedicals, Shiga, Japan) and subjected to PCR amplification on the iCycler iQ Real-Time 
Detection System (Bio-Rad Laboratories, Hercules, CA, USA) (1 cycle at 95 °C for 10 s and 50 
cycles at 95 °C for 5 s and 60 °C for 34 s). β-Actin expression was used to normalize the cDNA 
levels. The PCR products were analyzed using a melting curve to ascertain specificity of the 
amplification. The data were expressed as mean ± SD relative to the sham-operated nondiabetic group. 
2.8. Measurement of Total AA Level 
Total AA (AA + DHA) levels in the plasma and cortex have been determined by 
spectrophotometric method using Vitamin C Assay kit (ROIK02, Shima Laboratories, Tokyo, 
Japan) which is based on 2,4-dinitrophenylhydrazine method [33]. Briefly, plasma was mixed with 
an equal volume of 10% metaphosphoric acid solution. Cortex tissue was mixed with 14 times 
volume of 5.4% metaphosphoric acid solution and homogenized. After centrifugation of the 
solutions at 10,000× g for 15 min at 4 °C, the supernatants were used to the assay. 
2.9. Statistical Analysis 
Two-way ANOVA, followed by post hoc Tukey’s multiple-comparison test, was used for statistical 
analysis. Neurological deficit scores were analyzed using the Kruskal-Wallis test, followed by the 
Mann-Whitney U test. In all cases, a p value of <0.05 was assumed to denote statistical significance. 
3. Results 
3.1. Blood Glucose and Body Weight 
Body weight and blood glucose data from the experimental rats were obtained throughout the 
study period (Table 1). Similar to our previous study [25], the diabetic control group of rats had a 
significantly decreased body weight and an increased blood glucose level compared with the 
nondiabetic control group. There were no significant differences in those parameters between the 
AA-supplemented groups and their controls. 
Table 1. Effects of oral supplementation with AA on body weight and blood glucose 
levels in nondiabetic (non-DM) and diabetic (DM) groups of rats. 
Groups Body Weight (g) Blood Glucose (mg/dL) 
Non-DM 335 ± 16 112 ± 11 
Non-DM + AA 340 ± 23 135 ± 9 
DM 255 ± 32 * 485 ± 42 * 
DM + AA 269 ± 36 * 469 ± 71 * 
The data are shown as mean ± SD. * p < 0.01 vs. the nondiabetic group (n = 6–7). 
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3.2. Ischemic Brain Injury and Neurological Deficits 
Figure 1 shows MCAO/Re-induced brain injury in the nondiabetic control, nondiabetic + AA, 
diabetic control, and diabetic + AA groups of rats. Examples of TTC staining in the coronal brain 
sections at 24 h after MCAO/Re are shown in Figure 1A. The infarct developed in the corpus 
striatum and cortex of the nondiabetic control rats. In the diabetic rats, the infarction zone was 
remarkably enlarged and extended to a large part of the left striatum and cortex. In contrast, the 
infarcts in the AA-supplemented groups were smaller than those in their respective controls. 
Quantitative assays revealed that the infarct volume and edema in the diabetic control group were 
significantly increased by approximately 2.5-fold and 2-fold, respectively, compared with those in 
the nondiabetic control group (Figure 1B,C). AA supplementation in the nondiabetic group 
significantly decreased infarction and edema. Furthermore, AA almost completely suppressed the 
exacerbation of brain damage by diabetes. 
Figure 1. Effects of AA supplementation on infarction induced by MCAO/Re in the 
brain of nondiabetic and diabetic rats. (A) Representative photographs of staining of 
coronal brain sections from the rats of the nondiabetic + sham operation group and from 
distilled water-administered (Control) or AA (100 mg/kg)-supplemented nondiabetic or 
diabetic groups with MCAO with reperfusion (MCAO/Re). AA or water was orally 
administered once daily for 2 weeks; (B) Infarct volume in ischemic hemispheres of the 
diabetic and nondiabetic groups after MCAO/Re by TTC staining; (C) Edema volume in 
ischemic hemispheres of the diabetic and nondiabetic groups after MCAO/Re. Data are 
presented as means ± SD (n = 6–7). ** p < 0.01 compared with the nondiabetic control 
group. ## p < 0.01 compared with the diabetic control group. DM in the figure denotes 
diabetic, while non-DM denotes nondiabetic. 
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Consistent with the aforementioned results of the brain injury experiments, neurological deficits 
were exacerbated in the diabetic control group of rats (Figure 2). Compared with the diabetic control 
group, the diabetic + AA group showed significant alleviation of the neurological deficits. 
Figure 2. Effects of AA supplementation on neurological deficits induced by MCAO/Re 
in nondiabetic and diabetic rats. Postischemic neurological deficits were evaluated on a  
5-point scale at 24 h of reperfusion after 2 h of MCAO. Data are mean ± SD of 6–7 rats 
per group. ** p < 0.01 compared with the nondiabetic control group. ## p < 0.01 
compared with the diabetic control group. DM in the figure denotes diabetic, while 
non-DM denotes nondiabetic. 
 
3.3. O2– Production after Ischemia with Reperfusion 
Figure 3 shows fluorescence intensity of DHE in the penumbral cortex, which depends on 
intracellular O2– production. Representative histological images of DHE staining in the nondiabetic 
control, nondiabetic + AA, diabetic control, and diabetic + AA groups are shown in Figure 3A. 
DHE-positive cells with low fluorescence intensity were sparsely distributed in the cortex of 
sham-operated nondiabetic rats. In contrast, sham-operated diabetic rats had an increased number of 
DHE-positive cells with higher fluorescence intensity in the cortex, indicating basal augmentation 
of the generation of ROS in the brain of the diabetic rats. The intensity of DHE fluorescence was 
remarkably increased by MCAO/Re in the nondiabetic rats and was further augmented in the 
diabetic rats, suggesting that the exacerbated injury can be attributed to enhanced generation of 
ROS in diabetes. AA supplementation significantly reduced the fluorescence of DHE in the cortex 
of the nondiabetic and diabetic rats compared with that in their respective controls. 
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Figure 3. Effects of AA supplementation on production of O2– after MCAO/Re in the 
brain of nondiabetic and diabetic rats. (A) Representative photographs of superoxide 
production detected by DHE staining in coronal sections of the cortex from the nondiabetic 
and diabetic rats; (B) Quantitative analysis of DHE fluorescence intensity in the cortex. 
The data are presented as mean ± SD (n = 3–4). * p < 0.05, ** p < 0.01 compared with the 
nondiabetic control group. # p < 0.05, ## p < 0.01 compared with the diabetic control 
group. DM in the figure denotes diabetic, while non-DM denotes nondiabetic. 
 
3.4. Apoptosis Induced by Ischemia with Reperfusion 
Activation of caspase-3, a key mediator of the execution phase of apoptosis, was determined by 
immunostaining for cleaved caspase-3, which is an activated form of this enzyme, in the ischemic 
penumbral cortex of the four experimental groups after MCAO/Re (Figure 4). Compared with the 
nondiabetic control group, the number of cleaved caspase-3 positive cells was remarkably increased 
by MCAO/Re in the diabetic control group. AA significantly attenuated the MCAO/Re-induced 
activation of caspase-3 in the nondiabetic and diabetic groups. 
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Figure 4. Effects of AA supplementation on cleaved caspase-3 after MCAO/Re in the 
brain of nondiabetic and diabetic rats. (A) Representative photographs of cleaved 
caspase-3 immunostaining in the cortex coronal sections of nondiabetic and diabetic rats;  
(B) Quantitative analysis of cleaved caspase-3 positive cells (fluorescence intensity in 
the cortex). The data are presented as mean ± SD (n = 3–4). * p < 0.05, ** p < 0.01 
compared with the nondiabetic control group. ## p < 0.01 compared with the diabetic 
control group. DM in the figure denotes diabetic, while non-DM denotes nondiabetic. 
 
3.5. Expression of IL-1β, TNF-α, and MPO in the Cortex 
To assess the effects of AA supplementation on the expression of proinflammatory cytokines, 
we performed immunohistochemical staining for IL-1β and TNF-α. This experiment confirmed 
upregulation of the protein level of these cytokines as a result of MCAO/Re and diabetes (Figures 5 
and 6). Quantification of the immunostaining data showed that the sham-operated diabetic control 
group had a significant increase in IL-1β and TNF-α expression compared with the sham-operated 
nondiabetic control group, suggesting basal augmentation of the inflammatory response in the 
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diabetic brain. MCAO/Re significantly increased the expression levels of those proinflammatory 
cytokines in the nondiabetic cortex. The ischemia-induced upregulation of those cytokines was 
markedly accelerated by diabetes: the diabetic control group showed a 15.9- and 21.0-fold increase 
in IL-1β and TNF-α expression, respectively, compared with the nondiabetic control group. AA 
supplementation significantly suppressed the basal and ischemia-enhanced expression of these 
cytokines in diabetic rats. 
Figure 5. Effects of AA supplementation on expression of IL-1β in the penumbral cortex 
after MCAO/Re in the brain of nondiabetic and diabetic rats. (A) Representative 
photographs of IL-1β immunostaining (red fluorescence) and staining of nuclei by 
TO-PRO-3 (blue fluorescence) in the cortex coronal sections of nondiabetic and diabetic 
rats; (B) Quantitative analysis of IL-1β fluorescence intensity in the cortex. The data are 
presented as mean ± SD (n = 3–4). ** p < 0.01 compared with the nondiabetic control 
group. # p < 0.05 compared with the diabetic control group. DM in the figure denotes 
diabetic, while non-DM denotes nondiabetic. 
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Figure 6. Effects of AA supplementation on expression of TNF-α in the penumbral 
cortex after MCAO/Re in the brain of nondiabetic and diabetic rats. (A) Representative 
photographs of TNF-α immunostaining (red fluorescence) and staining of nuclei by 
TOPRO-3 (blue fluorescence) in the cortex coronal sections of nondiabetic and diabetic 
rats; (B) Quantitative analysis of TNF-α fluorescence intensity in the cortex. The data are 
presented as mean ± SD (n = 3–4). ** p < 0.01 compared with the nondiabetic control 
group. # p < 0.05 compared with the diabetic control group. DM in the figure denotes 
diabetic, while non-DM denotes nondiabetic. 
 
In the nondiabetic rat cortex, the protein expression of MPO was markedly upregulated after 
MCAO/Re (Figure 7). AA supplementation abrogated the ischemia-induced increase in MPO 
expression. Compared with the nondiabetic rats, the basal level of MPO expression increased only 
slightly in the diabetic rats. MCAO/Re upregulated the expression of MPO to the level similar to 
that in the nondiabetic group. AA supplementation had no effect on the ischemia-induced increase 
in the MPO level in the diabetic rats. 
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Figure 7. Effects of AA supplementation on MPO expression after MCAO/Re in the 
brain of nondiabetic and diabetic rats. (A) Representative photographs of MPO 
immunostaining in the cortex coronal sections of nondiabetic and diabetic rats;  
(B) Quantitative analysis of MPO fluorescence intensity in the cortex. The data are 
presented as mean ± SD (n = 3–4). * p < 0.05 compared with the nondiabetic control 
group. DM in the figure denotes diabetic, while non-DM denotes nondiabetic. 
 
3.6. Expression of SVCT2 and GLUT1 in the Cortex 
The expression and transport activity of SVCT2 as a specific transporter of AA in the CNS have 
been reported to be enhanced after MCAO/Re in mice [20]. In addition, DHA is known to be 
transported across the BBB via GLUT1 [19]; thus, we investigated effects of AA supplementation 
on changes in the expression of SVCT2 and GLUT1 mRNA in diabetic animals with or without 
MCAO/Re (Figure 8). There was no significant difference in the basal expression levels of SVCT2 
mRNA between the nondiabetic and diabetic groups or between each of them and their 
AA-supplemented groups. In the nondiabetic and nondiabetic + AA groups, the expression level of 
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SVCT2 mRNA was equally upregulated at 24 h after MCAO/Re. In contrast, the upregulation of 
ischemia-induced SVCT2 mRNA expression was not observed in the diabetic control group, 
whereas it was observed in the diabetic + AA group. Compared with the nondiabetic control group, 
the diabetic state significantly downregulated the expression of GLUT1 mRNA in the cortex. AA 
supplementation increased the expression of GLUT1 in the nondiabetic and diabetic rats. In the 
nondiabetic and diabetic control groups, MCAO/Re had a stimulating effect on the expression of 
GLUT1 mRNA that was similar to the effect of AA supplementation. Further enhancement by 
ischemia was not detected in the AA-supplemented groups. 
Figure 8. Effects of AA supplementation on SVCT2 and GLUT1 mRNA expression in 
the ischemic penumbral cortex of nondiabetic and diabetic rats. Expression levels of 
SVCT2 mRNA (Slc23a2) (A) and GLUT1 mRNA (Slc2a1) (B) were assessed using 
real-time PCR analysis of the penumbral cortex of nondiabetic and diabetic rats after 
MCAO/Re. The data are presented as mean ± SD (n = 3–6). † p < 0.05, †† p < 0.01 
compared with the respective sham-operated controls. * p < 0.05, ** p < 0.01. 
 
To assess the effects of AA supplementation on the expression of SVCT2 protein after 
MCAO/Re in detail, the localization and the expression levels of SVCT2 in the penumbral cortex 
were examined by immunohistochemical staining (Figure 9A). Double immunofluorescence 
staining with antibodies of anti-SVCT2 and anti-NeuN, a biomarker for neurons, revealed that 
majority of the cells exhibiting SVCT2 expressed NeuN in the sham-operated nondiabetic and 
diabetic rat cortex (Figure 9A). In addition, the cells exhibiting the endothelial cell maker RECA1 
showed a low level of SVCT2-immunoreactivity (Figure 9B). These expression levels in the 
neurons and capillary endothelial cells of SVCT2 were upregulated by MCAO/Re in the 
nondiabetic rats, but not in the diabetic rats. In agreement with the results from the mRNA 
measurement, quantification of the immunofluorescence revealed that the expression levels of 
SVCT2 immunoreactivity were significantly increased in response to MCAO/Re both in the 
nondiabetic control and AA-supplemented nondiabetic groups (Figure 9C). This reaction against 
MCAO/Re was abrogated in the diabetic control group, whereas the AA-supplemented diabetic rats 
showed an increased expression of SVCT2 in the cortex after MCAO/Re. 
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Figure 9. Effects of AA supplementation on SVCT2 and GLUT1 expression in the 
ischemic penumbral cortex of nondiabetic and diabetic rats. Expression levels of SVCT2 
(A–C) and GLUT1 (D,E) were assessed using immunohistostaining of the penumbral 
cortex of nondiabetic and diabetic rats after MCAO/Re. Immunohistochemical 
expression of SVCT2 (red fluorescence) merged with NeuN (A) or with RECA1  
(B) (green fluorescence); (C) Quantitative analysis of SVCT2 fluorescence intensity in 
the cortex. # p < 0.05, ## p <  0.01. * p < 0.05, ** p < 0.01 compared with the respective 
sham-operated nondiabetic controls; (D) Immunohistochemical expression of GLUT1 
(red fluorescence) merged with RECA1 (green fluorescence); (E) Quantitative analysis 
of SVCT2 fluorescence intensity in the cortex. * p < 0.05, ** p < 0.01 compared with the 
respective sham-operated nondiabetic controls. † p < 0.05, †† p < 0.01 compared with the 
respective sham-operated diabetic controls. 
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Figure 9. Cont. 
 
On the other hand, GLUT1 immunoreactivity was predominantly colocalized with RECA1  
(Figure 9D). Some of the cells exhibiting NeuN showed a weak GLUT1-immunoreactivity (data not 
shown). In the sham-operated nondiabetic and diabetic groups with AA supplementation, the 
expression levels of GLUT1 in the capillary endothelial cells were remarkably upregulated. 
Additionally, MCAO/Re showed a stimulating effect on the GLUT1 expression both in the 
nondiabetic and diabetic cortex. Quantitative analyses of immunofluorescence in the sections 
revealed that the sham-operated diabetic control rat cortex had a lower expression level of GLUT1 
compared with the nondiabetic rat cortex, and AA supplementation or MCAO/Re caused a 
significant increase in the expression of GLUT1 (Figure 9E). 
3.7. Total AA Levels in the Plasma and Cortex 
To determine whether the changes in expression levels of SVCT2 and GLUT1 induced by AA 
supplementation or by MCAO/Re affect the concentrations of AA in the cortex, we measured total 
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AA (AA + DHA) levels in the plasma and cortex of the experimental groups (Figure 10). It has been 
indicated that reduction of DHA to AA or decomposition of DHA to 2,3-diketo-1-gulonic acid is 
rapid in the plasma and brain, and that the concentrations of DHA in these tissues are 0%–2% of  
AA [19]. Therefore, total AA levels are considered to almost equal to the AA levels. The plasma of 
the sham-operated diabetic control rats had a significant smaller amount of total AA levels compared 
with the nondiabetic rats (Figure 10A). AA supplementation restored the decrement of the total AA 
levels in the diabetic rats to almost the same levels as those in the nondiabetic control rats. 
MCAO/Re had little effect on the total AA levels in the plasma of all groups. In contrast, neither 
diabetic state nor AA supplementation affected the total AA levels in the cortex of sham-operated 
groups. MCAO/Re significantly decreased the total AA levels both in the nondiabetic and diabetic 
cortex. AA supplementation to the diabetic rats caused a significant increase in the total AA levels in 
the cortex in response to MCAO/Re. 
Figure 10. Effects of AA supplementation on levels of total AA (AA + DHA) in the 
plasma and cortex of nondiabetic and diabetic rats. Total AA (AA + DHA) levels in the 
plasma (A) and cortex (B) measured in nondiabetic and diabetic rats after MCAO/Re. 
The data are presented as mean ± SD (n = 3–6). * p < 0.05, ** p < 0.01. 
 
4. Discussion 
The present study confirmed that the STZ-evoked diabetic state aggravates neuronal damage 
caused by a transient cerebral ischemia and subsequent reperfusion in rats. We found that diabetes 
enhances the production of O2−, activates caspase-3, and induces the expression of proinflammatory 
cytokines (TNF-α and IL-1β) in the brain. These detrimental effects are markedly potentiated by 
cerebral ischemia and reperfusion, leading to greater infarct growth and aggravation of apoptosis 
and inflammation. Our results show that chronic supplementation with AA inhibits the apoptotic 
changes and proinflammatory responses, and attenuates the exacerbation of cerebral injury and 
neurological deficits in the diabetic state. These beneficial effects of AA could be attributed to its 
antioxidant and anti-inflammatory properties. We observed that the expression level of SVCT2 
increases in response to MCAO/Re in the nondiabetic cortex, which is accompanied by an increase 
in the total AA (AA + DHA) in the tissues, and that these responses are abolished in the diabetic 
rats. AA supplementation to the diabetic rats restored these responses to the levels of the 
nondiabetic rats. Therefore, supplementation with AA may enhance the transport of AA into 
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neuronal cells, resulting in reinforcement of the antioxidant defense and alleviation of oxidative 
ischemic injury in the brain of diabetic rats. 
Because rats can synthesize their own AA, unlike humans, they seem to hardly suffer from low 
levels of internal AA [19]. However, there is experimental evidence that STZ-induced type 1 
diabetic rats have low levels of AA in the plasma, liver, kidney, and other tissues [23,34,35]. It is 
conceivable that the enhanced oxidative stress in diabetes consumes the circulating AA and that the 
resulting diminution in the AA concentration leads to further enhancement of the reactions 
mediated by free radicals. This study indicates that the diabetic rats have low levels of AA in the 
plasma, and that chronic oral pretreatment with AA in diabetic rats decreases the cerebral O2− 
generation, apoptosis, and infarction induced by MCAO/Re; all of these effects could be a result of 
improved antioxidant status in the diabetic brain. Indeed, we observed that AA supplementation to 
the diabetic rats prevents the diminution of the total AA levels in the cortex associated with 
ischemia-reperfusion. On the other hand, we found that AA supplementation causes insufficient 
downregulation of proinflammatory cytokines and has no effect on MPO expression in diabetic rats 
after MCAO/Re. The relative low dose of AA (100 mg/kg) which we used in this study might  
not be efficacious against the severe inflammatory responses induced by the combination of stroke 
and diabetes. 
Concentrations of AA in plasma and peripheral extracellular fluid after ingestion are strictly 
controlled by intestinal absorption, tissue transport, and renal excretion. Chen et al. [36] shows that 
orally administrated AA at doses >200 mg/kg is declined to ≈60 μM in plasma and extracellular fluid 
of femoral muscle in rats. In the brain, concentration of AA is relatively high compared with that in 
the plasma [24]. Two mechanisms of AA recruitment into the brain are known: the transport of AA 
through SVCT2, a specific transporter for AA, and the transport of DHA across the BBB through 
GLUT1 with subsequent immediate reduction in the brain. The gradation of AA concentrations 
between the plasma and the CNS is thought to be maintained by SVCT2, because AA is mainly 
present in the reduced form in the plasma. On the other hand, the cerebroprotective effects of AA 
supplementation remain controversial, whereas beneficial effects of DHA administration for 
neuronal oxidative stress and inflammation seem to be well established [37–39]. Previous studies 
do not support acute cerebroprotective effects of treatment with AA under normal conditions 
because AA is not transported into the brain rapidly, owing to the high affinity and low ability for 
AA transport by SVCT2. Ahn and colleagues [40] reported that chronic AA supplementation has 
little or no effect on elevated oxidative stress in STZ-induced diabetic brain, whereas it is 
efficacious in the liver and kidneys. This phenomenon can be attributed to a lack of SVCT2 
expression in endothelial cells of the BBB [41,42]. Recently, the evidence indicating that AA 
supplementation suppresses diabetes or ischemia-induced oxidative damage in the hippocampus 
and cortex of experimental animals has been accumulated [43–45]. These regions are not only 
vulnerable to oxidative stress but abundant in SVCT2 compared to other regions in the brain, 
namely, there may be some kinds of differences in sensitivity for AA supplementation depending 
on brain regions. Therefore, it seems possible that previous experiments using whole-brain samples 
might have not been adequate to detect the cerebroprotective effects of AA supplementation. 
The system of DHA transport through GLUT1 in the BBB may not substantially contribute to 
total brain AA concentrations under normal conditions, because DHA concentrations in the plasma 
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are usually only 0%–2% of AA concentrations [19,46]. Nonetheless, during oxidative stress in the 
CNS such as stroke and/or treatment with DHA, this route could play a significant role in the 
recruitment of AA [39,47]. Our study demonstrated that diabetes downregulates the expression of 
GLUT1 in the cortex, in line with previous studies [21,25]. AA supplementation to the diabetic rats 
markedly upregulated the basal expression of GLUT1; however, it exerted no significant increase 
in the total AA levels in the cortex of the rats. Taken together, contribution of the DHA transport 
system through GLUT1 to the cerebroprotection seems to be limited in the diabetic rats. The 
upregulation of GLUT1 expression by AA supplementation was observed also in the cortex of 
nondiabetic sham-operated group, despite that there were little changes in the total AA levels in the 
plasma of the rats. These results may indicate that orally supplemented AA has no direct enhancing 
effect on the expression of GLUT1 in the nondiabetic rats. However, AA concentration in the 
plasma is considered to increase within several hours after oral administration and decline to the basal 
level 24 h after the administration by excretion of the excess of AA, at which we collected the plasma 
samples from the experimental animals. Therefore, one possibility is that intermittent increases in 
AA concentration in the plasma repeated for two weeks could stimulate expression of GLUT1 in the 
cortex. Future research needs to be done with regard to the detailed mechanism underlying the 
upregulation of GLUT1 expression by AA supplementation. 
SVCT2 has been shown to be crucial for maintaining AA for protection against oxidative stress 
in the CNS. It has been shown that cultured cells lacking this protein are vulnerable to oxidative  
stress [18]. In the present study, diabetes itself caused no apparent changes in the expression of 
SVCT2 in the cortex. On the other hand, after MCAO/Re, the expression of SVCT2 in the 
penumbral cortex, of which the majority seems to be localized in neurons, is upregulated in the 
nondiabetic rats. Gess and colleagues [20] have demonstrated that SVCT2 is specifically expressed 
in brain capillary endothelial cells and transports AA across the BBB during the subacute phase after 
MCAO/Re in mice. We also observed that expression levels of SVCT2 in capillary endothelial 
cells are increased after MCAO/Re in the nondiabetic rat cortex. This has been proposed as one of 
the mechanisms that protect the brain against oxidative injury under pathological conditions such as 
stroke and neurodegeneration. In contrast, we found that the upregulation of SVCT2 expression was 
abrogated in the diabetic rats, suggesting that the cerebroprotective mechanism via AA recruitment 
may be disrupted in the diabetic state. The abnormality of endothelial cell function in STZ-diabetic 
rats has been indicated to be related to the ROS generation in microvascular walls [17]. Seno and 
coworkers [48] demonstrated that the inflammatory cytokines TNF-α and IL-1β suppress the 
transport of AA through SVCT2 in human umbilical vein endothelial cells. Indeed, we detected a 
robust increase in the expression these cytokines in the brain of diabetic rats after MCAO/Re, 
which may reverse the upregulation of SVCT2 by MCAO/Re itself. AA supplementation to the 
diabetic rats upregulated the expression of SVCT2 in the cortex and restored the total AA levels to 
the nondiabetic levels. The antioxidative properties of AA may protect endothelial functions 
including the transcriptional regulation of SVCT2 against the exacerbated ischemic oxidative injury 
and the enhanced proinflammatory responses in the diabetic state, and may improve AA transport 
through SVCT2 in the BBB. Further experiments using radiolabeled tracers or other rodent models 
such as SVCT2+/− mice are needed to elucidate these cerebroprotective mechanisms of AA, 
including its effects on the specific transport of AA into the diabetic brain. 
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5. Conclusions 
In the present study, we found that chronic AA supplementation inhibits the apoptotic and 
proinflammatory changes and attenuates the exacerbation of cerebral injury and neurological 
deficits in the diabetic state. These phenomena could be attributed to the antioxidant activity and  
anti-inflammatory effects of AA. Diabetes repressed the enhancement of SVCT2 expression 
induced by ischemia-reperfusion in the neurons and capillary endothelial cells, whereas the 
downregulated expression of SVCT2 was restored to control levels by AA supplementation. 
Therefore, chronic AA supplementation may enhance and normalize the transport of AA into the 
CNS and may thus reinforce the antioxidant defense and alleviate oxidative ischemic injury in the 
brain of diabetic rats. 
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